Literature DB >> 8658378

Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension.

S J Brett1, J Simon, R Gibbs, J R Pepper, T W Evans.   

Abstract

BACKGROUND: Pulmonary vascular tone may be modulated by endothelium-derived vasoactive mediators. Endothelial dysfunction is thought to occur in primary pulmonary hypertension. The aim of this study was to evaluate the vascular responses of patients with severe primary pulmonary hypertension to endothelium-dependent vasodilators (for example, substance P) and non-endothelium-dependent vaasodilators (for example, adenosine).
METHODS: Six patients with primary pulmonary hypertension (mean (SE) systolic, diastolic, and pulmonary artery pressures 91.1 (7), 45.2 (3), and 62 (4.2) mm Hg, respectively, and baseline total pulmonary vascular resistance (TPVR) 1949 (164) dynes.s.cm-5) underwent sequential infusions of substance P (5-100 pmol/min) and adenosine (5-50 micrograms/kg/min) in random order. Pulmonary and systemic haemodynamics were monitored by indwelling radial and pulmonary arterial catheters.
RESULTS: Substance P caused a marked fall in systemic vascular resistance (SVR) but minimal pulmonary vasodilation (mean maximal percentage change from baseline in TPVR:SVR ratio 27.85 (6.5)%, p < 0.01). Adenosine caused TPVR to fall, but resulted in no change in SVR (mean maximum percentage change from baseline in TPVR:SVR ratio -9.85 (3.5)%, p < 0.05).
CONCLUSION: Endothelium-dependent vasodilation is deficient in the pulmonary circulation of patients with primary pulmonary hypertension and may contribute to the abnormalities of pulmonary vascular tone and reactivity seen in that condition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8658378      PMCID: PMC472808          DOI: 10.1136/thx.51.1.89

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Endothelial dysfunction in pulmonary hypertension.

Authors:  J Loscalzo
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

2.  Adenosine and selective reduction of pulmonary vascular resistance in primary pulmonary hypertension.

Authors:  J T Reeves; B M Groves; E K Weir
Journal:  Circulation       Date:  1991-09       Impact factor: 29.690

Review 3.  Primary pulmonary hypertension.

Authors:  S Rich
Journal:  Prog Cardiovasc Dis       Date:  1988 Nov-Dec       Impact factor: 8.194

4.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension.

Authors:  J Pepke-Zaba; T W Higenbottam; A T Dinh-Xuan; D Stone; J Wallwork
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

5.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

6.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

Authors:  B W Christman; C D McPherson; J H Newman; G A King; G R Bernard; B M Groves; J E Loyd
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

7.  Adenosine as a vasodilator in primary pulmonary hypertension.

Authors:  J M Morgan; D G McCormack; M J Griffiths; C J Morgan; P J Barnes; T W Evans
Journal:  Circulation       Date:  1991-09       Impact factor: 29.690

8.  Response of the pulmonary circulation to acetylcholine, calcitonin gene-related peptide, substance P and oral nicardipine in patients with primary pulmonary hypertension.

Authors:  N G Uren; P F Ludman; T Crake; C M Oakley
Journal:  J Am Coll Cardiol       Date:  1992-03-15       Impact factor: 24.094

9.  Comparison of neurokinin A and substance P on cardiovascular and airway function in man.

Authors:  T W Evans; C M Dixon; B Clarke; T B Conradson; P J Barnes
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

  9 in total
  6 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

2.  Endothelium-dependent relaxation followed by contraction mediated by NK(1) receptors in precontracted rabbit intrapulmonary arteries.

Authors:  H Shirahase; M Kanda; K Kurahashi; S Nakamura
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 3.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

Review 4.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 5.  Endothelial cells in the pathogenesis of pulmonary arterial hypertension.

Authors:  Colin E Evans; Nicholas D Cober; Zhiyu Dai; Duncan J Stewart; You-Yang Zhao
Journal:  Eur Respir J       Date:  2021-09-02       Impact factor: 33.795

Review 6.  The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension.

Authors:  Charmaine C W Lo; Seyed M Moosavi; Kristen J Bubb
Journal:  Front Physiol       Date:  2018-08-23       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.